Private company

Meridian Bioscience

American medical equipment company based in Cincinnati, incorporated in Ohio. Summary from the record

Last updated Oct 19, 2026.

Overview

1977Founded1
  • Industrymedical equipment1
  • HeadquartersCincinnati1
  • Listed onNasdaq (VIVO)1
  • Legal formCorporation (For-Profit)3
  • LEI549300ELSRZEFFFRX1953
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O CORPORATION SERVICE COMPANY, 43221 Columbus, United States3
  • Registered withCorporation Database (Ohio Secretary of State), 4833763

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

56.6%Gross margin4
16.3%Operating margin4
12.7%Net margin4
4.8%Revenue growth, 20224
11.5%Return on equity4
0.07×Debt to equity4
$73.7MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Vehicle spec conversion [member] brought in 82% of the revenue Meridian Bioscience broke down this way in fiscal 2025.

  1. Vehicle spec conversion [member]$50.0K582%
  2. Digital Asset Revenue$8.0K513%
  3. Conversion kits [member]$3.0K55%down 81% from 2024
Products and services by year
Products and services202320242025
Vehicle spec conversion [member]$50.0K
Digital Asset Revenue$8.0K
Conversion kits [member]$1.4M$16.0K$3.0K

Regions

AUMember brought in 87% of the revenue Meridian Bioscience broke down this way in fiscal 2025.

  1. AUMember$53.0K587%
  2. United States$8.0K513%
Regions by year
Regions202320242025
AUMember$2.6M$53.0K
United States$8.0K

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue43¢$144.7M
  • Research and development7¢$24.3M
  • Other costs33¢$108.5M
  • Interest0¢$1.2M
  • Income tax4¢$11.9M
  • Profit13¢$42.5M

Out of $333.0M in revenue.4

Where each dollar of operating cash went, fiscal 2022

  • Capital spending10¢$8.6M
  • Kept or used elsewhere90¢$73.7M

Out of $82.4M of cash from operations.4

Financial statements

Revenue67894$333.0M in 2022+70% since 2016
0$100.0M$200.0M$300.0M$400.0M2016: $196.1M$196.1M20162017: $200.8M$200.8M2017+2%2018: $213.6M$213.6M2018+6%2019: $201.0M$201.0M2019−6%2020: $253.7M$253.7M2020+26%2021: $317.9M$317.9M2021+25%2022: $333.0M$333.0M2022+5%
Gross profit67894$188.4M in 2022+48% since 2016
0$100.0M$200.0M$300.0M2016: $127.2M$127.2M20162017: $124.3M$124.3M2017−2%2018: $131.0M$131.0M2018+5%2019: $118.7M$118.7M2019−9%2020: $156.2M$156.2M2020+32%2021: $201.1M$201.1M2021+29%2022: $188.4M$188.4M2022−6%
Operating income67894$54.4M in 2022+6% since 2016
0$25.0M$50.0M$75.0M$100.0M2016: $51.4M$51.4M20162017: $37.4M$37.4M2017−27%2018: $31.6M$31.6M2018−16%2019: $32.7M$32.7M2019+4%2020: $61.3M$61.3M2020+88%2021: $93.0M$93.0M2021+52%2022: $54.4M$54.4M2022−42%
Net income67894$42.5M in 2022+32% since 2016
0$20.0M$40.0M$60.0M$80.0M2016: $32.2M$32.2M20162017: $21.6M$21.6M2017−33%2018: $23.8M$23.8M2018+11%2019: $24.4M$24.4M2019+2%2020: $46.2M$46.2M2020+89%2021: $71.4M$71.4M2021+55%2022: $42.5M$42.5M2022−41%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-06-302024-06-302023-06-30
Revenue from contracts with customers$61.0K$16.0K$4.1M
Cost of sales-$50.0K$27.0K-$4.3M
Cost of sales - non-recurring events-$3.9M
Gross profit/(loss)$11.0K$43.0K-$4.1M
General and administrative expenses-$8.2M-$7.5M-$6.4M
Other gains$16.0K$89.0K$31.0K
Other income$82.0K
Depreciation of property, plant and equipment-$157.0K-$746.0K-$508.0K
Amortization of intangible assets-$360.0K-$384.0K-$831.0K
Operating loss-$8.7M-$8.5M-$11.7M
Restructuring and other non-recurring costs-$412.0K-$1.4M-$1.7M
Impairment losses-$2.5M-$29.7M-$421.0K
Finance income$3.6M$1.4M$1.2M
Finance expense-$7.0M-$6.0M-$6.8M
Loss before income tax-$15.1M-$44.2M-$19.5M
Income tax$691.0K-$1.6M-$559.0K
Loss from continuing operations-$14.4M-$45.8M-$20.1M
(Loss)/profit from discontinued operations$1.6M-$881.0K-$4.3M
Loss for the period-$12.8M-$46.7M-$24.4M
Equity owners of VivoPower International PLC-$12.8M-$46.7M-$24.4M
Currency translation differences recognized directly in other comprehensive loss-$2.0M-$1.2M$1.2M
Total comprehensive loss for the period attributable to owners of the company-$14.8M-$47.9M-$23.1M
Continuing Operations - Basic-$2.17-$14.88-$8.13
Continuing Operations - Diluted-$2.17-$14.88-$8.13
Discontinued Operations - Basic$0.25-$0.29-$1.74
Discontinued Operations - Diluted$0.25-$0.29-$1.74

Compare Meridian Bioscience with another company

Leadership

Who has led Meridian Bioscience, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William J. Motto2006–2008
  2. John A. Kraeutler2008–2017
  3. Amy Winslow2016–2017
  4. John P. Kenny2017–2023

Chair

  1. William J. Motto2006–2014
  2. John A. Kraeutler2014–2017

President

  1. Antonio Interno2006
  2. John A. Kraeutler2006–2007

Chief financial officer

  1. Melissa Lueke2006–2019
  2. Bryan T. Baldasare2019–2021
  3. Andrew S. Kitzmiller2022–2023

Chief operating officer

  1. John A. Kraeutler2006–2007
19801990200020102020
Board members and other officers (24)

Timeline

  1. Oct 11, 2017New chief executive John P. Kenny becomes CEO14
  2. Mar 28, 2016New chief executive Amy Winslow becomes CEO15
  3. Feb 1, 2008New chief executive John A. Kraeutler becomes CEO16
  4. Jan 26, 2006New chief executive William J. Motto becomes CEO17
  5. Feb 26, 1992Went public Listed on NASDAQ1
  6. 1977Founded Founded1

Filings

135 filings to the SEC since October 2021: 3 annual reports, 4 quarterly reports, 19 major events, 52 insider forms, 22 large holders, 35 other. The latest 20:

  1. Feb 13, 202315-12G EDGAR
  2. Feb 9, 202310-Q EDGAR
  3. Feb 9, 2023SC 13G/A SCHEDULE 13G/A EDGAR
  4. Feb 3, 2023EFFECT EDGAR
  5. Feb 3, 2023EFFECT EDGAR
  6. Feb 3, 2023EFFECT EDGAR
  7. Feb 3, 2023EFFECT EDGAR
  8. Feb 3, 2023EFFECT EDGAR
  9. Feb 3, 2023SC 13D/A EDGAR
  10. Feb 2, 2023S-8 POS EDGAR
  11. Feb 2, 2023S-8 POS EDGAR
  12. Feb 2, 2023S-8 POS EDGAR
  13. Feb 2, 2023S-8 POS EDGAR
  14. Feb 2, 2023S-8 POS EDGAR
  15. Feb 2, 2023S-8 POS EDGAR
  16. Feb 2, 2023S-8 POS EDGAR
  17. Feb 2, 2023S-8 POS EDGAR
  18. Feb 2, 2023S-8 POS EDGAR
  19. Feb 2, 2023S-8 POS EDGAR
  20. Feb 2, 2023S-8 POS EDGAR

The 135 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 1 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 27, 2022Kenny John P.Chief Executive OfficerSale61,437$30.39$1.9MForm 4
Jun 24, 2022Kenny John P.Chief Executive OfficerSale13,559$30.00$406.8KForm 4
Jun 23, 2022Kenny John P.Chief Executive OfficerSale19,956$29.98$598.3KForm 4
Jun 22, 2022Kenny John P.Chief Executive OfficerSale44,651$29.72$1.3MForm 4
Feb 25, 2022Kitzmiller Andrew S.Executive Vice President & CFOBuy4,028$24.87$100.2KForm 4
Feb 15, 2022WELTZIEN LOURDESExecutive VP, Life ScienceSale20,000$25.60$512.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Members of Congress who traded it

5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Feb 23, 2021Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+196.7%Report
Nov 13, 2020Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+212.0%Report
Sep 16, 2020Tom MalinowskiDemocratic, HousePartial sale$1,001 - $15,000+224.3%Report
Sep 15, 2020Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+223.3%Report
Aug 31, 2020Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+218.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52